NDC product
Acyclovir
NDC 0093-3630 · Teva Pharmaceuticals USA, Inc.
Key facts
| Product NDC | 0093-3630 |
|---|---|
| Proprietary name | Acyclovir |
| Nonproprietary name | acyclovir |
| Substances | ACYCLOVIR |
| Dosage form | CREAM |
| Route | TOPICAL |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Application number | NDA021478 |
| Pharmacologic classes | DNA Polymerase Inhibitors [MoA], Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Nucleoside Analog [EXT] |
| Marketing start | Aug 29, 2019 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: